E.G. Armitage
A complex interplay between sphingolipid and sterol metabolism revealed by perturbations to the Leishmania metabolome caused by miltefosine
Armitage, E.G.; Alqaisi, A.Q.I.; Godzien, J.; Pena, I.; Mbekeani, A.J.; Alsonso-Herranz, V.; Lopez-Gonzalvez, A.; Martin, J.; Gabarro, R.; Denny, P.W.; Barrett, M.P.; Barbas, C.
Authors
A.Q.I. Alqaisi
J. Godzien
I. Pena
A.J. Mbekeani
V. Alsonso-Herranz
A. Lopez-Gonzalvez
J. Martin
R. Gabarro
Professor Paul Denny p.w.denny@durham.ac.uk
Professor
M.P. Barrett
C. Barbas
Abstract
With the World Health Organization reporting over 30,000 deaths and 200-400,000 new cases annually, visceral Leishmaniasis is a serious disease affecting some of the world's poorest people. As drug resistance continues to rise, there is a huge unmet need to improve treatment. Miltefosine remains one of the main treatments for Leishmaniasis, yet its mode of action (MoA) is still unknown. Understanding the MoA of this drug and parasite response to treatment could help pave the way for new, more successful treatments for Leishmaniasis. A novel method has been devised to study the metabolome and lipidome of Leishmania donovani axenic amastigotes treated with miltefosine. Miltefosine caused a dramatic decrease in many membrane phospholipids (PLs), in addition to amino acid pools, while sphingolipids (SLs) and sterols increased. Leishmania major promastigotes devoid of SL biosynthesis through loss of the serine palmitoyl transferase gene (ΔLCB2) were 3-fold less sensitive to miltefosine than WT parasites. Changes in the metabolome and lipidome of miltefosine treated L. major mirrored those of L. donovani. A lack of SLs in the ΔLCB2 was matched by substantial alterations in sterol content. Together these data indicate that SLs and ergosterol are important for miltefosine sensitivity and perhaps, MoA.
Citation
Armitage, E., Alqaisi, A., Godzien, J., Pena, I., Mbekeani, A., Alsonso-Herranz, V., …Barbas, C. (2018). A complex interplay between sphingolipid and sterol metabolism revealed by perturbations to the Leishmania metabolome caused by miltefosine. Antimicrobial Agents and Chemotherapy, 62(5), e02095-17. https://doi.org/10.1128/aac.02095-17
Journal Article Type | Article |
---|---|
Acceptance Date | Jan 21, 2018 |
Online Publication Date | Feb 20, 2018 |
Publication Date | May 1, 2018 |
Deposit Date | Nov 27, 2017 |
Publicly Available Date | Mar 7, 2018 |
Journal | Antimicrobial Agents and Chemotherapy |
Print ISSN | 0066-4804 |
Electronic ISSN | 1098-6596 |
Publisher | American Society for Microbiology |
Peer Reviewed | Peer Reviewed |
Volume | 62 |
Issue | 5 |
Article Number | e02095-17 |
Pages | e02095-17 |
DOI | https://doi.org/10.1128/aac.02095-17 |
Public URL | https://durham-repository.worktribe.com/output/1339297 |
Files
Published Journal Article
(1.8 Mb)
PDF
Publisher Licence URL
http://creativecommons.org/licenses/by/4.0/
Accepted Journal Article
(2.5 Mb)
PDF
Publisher Licence URL
http://creativecommons.org/licenses/by/4.0/
Copyright Statement
© 2018 Armitage et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.
You might also like
Rapid genotyping of Toxoplasma gondii isolates via Nanopore-based multi-locus sequencing
(2024)
Journal Article
TREATMENT OF LEISHMANIASIS
(2024)
Patent
Clemastine/tamoxifen hybrids as easily accessible antileishmanial drug leads
(2024)
Journal Article